A Clinical Study to see The Efficacy of Shallaki And Sanjivani Vati in Mono Articular Non-Specific Knee Effusion

A Randomized Clinical Study on The Efficacy of Shallaki And Sanjivani Vati in Mono Articular Non-Specific Knee Effusion

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/06/019696

Enrollment

Registered

2019-06-17

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E669- Obesity, unspecified

Interventions

Intervention1: Tab SHALLAKI AND SANJIVANI VATI AND ACECLOFENAC 100MG: Group I Patients will be given crude extract of Shallaki (Boswellia serrata Linn.) - 1000 mg thrice daily in form of capsule for

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of the age group 16-60 years for demographic analysis and 30-65 years for clinical study having Mono articular non-specific knee effusion visiting the OPD and willing to provide written, informed consent will be subjected to the study on the basis of specially prepared proforma including relevant parametres. 2.Patients will be selected randomly,irrespective of gender,economical,educational and marital status. 3.Patient ready to give written informed consent.

Exclusion criteria

Exclusion criteria: 1.Patients not ready to give an informed consent. 2.Patients not fullfilling the inclusion criteria. 3.Patients suffering from Mono articular specific knee effusion mainly tubercular,varioous types of specific arthritis,infections,conditions like post traumatic knee haem arthrosis. 4.Patients suffering from any kind of Malignancy,Diabetes,Cardiac disorder,HIV,etc. 5.Patients who are on steroids or there is history of prolonged steroids use or chemotherapeutic agents.

Design outcomes

Primary

Measure	Time frame
The outcome of the study will be analysed and evaluated in the pure view of aforesaid subjective and objective parameters in accordance with the standard research norms of statistics.Timepoint: 28 days	—

Secondary

Measure	Time frame
to see any additional benefit of the trial drugsTimepoint: 28 days	—

Countries

India

Contacts

Public ContactDR NARENDRA SINGH

NATIONAL INSTITUTE OF AYURVEDA JAIPPUR,RAJASTHAN

narinder.1973@gmail.com9549370912

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026